Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Leuprolide Acetate 45 mg in Central Precocious Puberty
NCT06926933Phase 4Active, not recruiting
- Sponsor
- HanAll Biopharma
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by HanAll Biopharma. Primary endpoint: Percentage of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test at 24 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT06926933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926933.